Trial Profile
A Multicentric, Comparative Controlled, Randomized, Parallel-Group, Phase III Study to Evaluate the Safety and Efficacy of FDC Containing Rosuvastatin Calcium and Telmisartan on Mild to Moderate Hypertension in Dyslipidemic Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs Rosuvastatin/telmisartan (Primary) ; Rosuvastatin; Telmisartan
- Indications Dyslipidaemias; Essential hypertension
- Focus Therapeutic Use
- Sponsors Biocon
- 07 Mar 2013 Status changed from not yet recruiting to completed as reported by Clinical Trials Registry - India.
- 17 Feb 2012 New trial record